comprehensive -WSS

comprehensive

author：fashion 2025-08-12 11:29:33 - browse：6

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Walensky prepares to leave CDC — and Congress — behind
Next article： He's a Nobel laureate. Critics say he was misleading on Covid

entertainment

WSS

Why palliative psychiatry is worth discussing

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

A common UTI test for kids haunts adults as a traumatic 'nightmare'

How medical schools plan to diversify without affirmative action

Medicare inequities exacerbate Puerto Rico’s health disparities

Acelyrin, a rare IPO success, stumbles in its first big test

knowledge

comprehensive

entertainment

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

Annovis Bio delivers candor, but not confidence, on Parkinson’s study

Medicare details structure of new drug price negotiation program

Listen: Covid's latest surge, Alnylam at the FDA, & the end of an era

Supreme Court strikes down use of affirmative action

Readout Newsletter: Wegovy, dialysis, Humira, Vir, and more

Peter Hotez and the public health issue of online harassment

R1 RCM gets $5.8 billion buyout offer from private equity firm

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Diverse clinical trials: Why aren’t we there yet?

focus

He's a Nobel laureate. Critics say he was misleading on Covid

Ocular Therapeutix moves raise hopes, and Alnylam tries to calm some nerves

Will the IRA bring competition to the biologics market?

Cyberattack on UnitedHealth subsidiary cripples pharmacies, hospitals

WATCH: Why do bright lights make us see spots?

New weight loss drugs vying to be the next Wegovy or Mounjaro

Wikipedia

entertainment

focus

hotspot